Dame Emma Walmsley, the chief executive, said the spin-off of Haleon, GSK’s consumer healthcare business, in July would start a new period of growthSupplies of a Covid antibody treatment and a recovery in sales of a blockbuster shingles vaccine helped to lift quarterly sales at GlaxoSmithKline by a third, boosting its shares before the break-up of the drugs group this summer. Sales rebounded by 32 per cent to almost £9.8 billion and adjusted operating profit by 39 per cent to £2.6 billion, ahead of City forecasts and helped by a favourable comparison with last year when the pandemic disrupted trading. SponsoredDame Emma Walmsley, the chief executive, said it was a strong first quarter in a “landmark year” for GSK. Walmsley, 52, said GSK remained on course to spin off Haleon, the new name given to its consumer healthcare business, on the London Stock Exchange in July, which would

Source: The Times April 28, 2022 00:45 UTC